• 1
    Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 5015.
  • 2
    Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 5337.
  • 3
    Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 118386.
  • 4
    Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 107679.
  • 5
    Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 549.
  • 6
    Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of literature. Ann Intern Med 1993; 118: 95663.
  • 7
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 147782.
  • 8
    Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 33842.
  • 9
    Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10 Suppl 1: S912.
  • 10
    Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997; 54 Suppl 3: 3240.
  • 11
    Lysaght M. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13 Suppl 1: S3740.
  • 12
    Eknoyan G. On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes. Am J Kidney Dis 1998; 32: S1S4.
  • 13
    Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 45456.
  • 14
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 64858.
  • 15
    Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999, 55: 1899911.
  • 16
    Zoccali C, Benedetto FA, Mallamaci F, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens 2000; 18: 120713.
  • 17
    Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 46976.
  • 18
    Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif 2002; 20: 7080.
  • 19
    Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 13841.
  • 20
    Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 60914.
  • 21
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996, 7: 72836.
  • 22
    Kistler JP, Ropper AH, Martin JB. Cerebrovascular diseases In: IsselbacherKJ, BraunwaldE, WilsonJD, MartinJB, FauciAS, KasperDL eds Harrison's Principles of Internal Medicine. 13th edn. New York: McGraw-Hill, 1994; 223356.
  • 23
    US Renal Data System: USRDS 1999 Annual data Report. VI Causes of Death. Am J Kidney Dis 1999; 34 (Suppl 1): S87S94.
  • 24
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 5361.
  • 25
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium ×phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 60717.
  • 26
    Bergstrom J, Lindholm B. Malnutrition, Cardiac Disease, and Mortality: An Integrated Point of View. Am J Kidney Dis 1998; 32: 83441.
  • 27
    Sechi LA, Zingaro L, Catena C, De Marchi S. Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events. Thromb Haemost 2000; 84: 56570.
  • 28
    Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38 (4 Suppl 1): S749.
  • 29
    Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 23: 82835.
  • 30
    Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91101.
  • 31
    Oda H, Ohno M, Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial 2000; 16: 15255.
  • 32
    Wang AY, Woo J, Wang M, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12: 192736.
  • 33
    Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001; 16: 144247.
  • 34
    Boaz M, Matas Z, Biro A, et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 43844.
  • 35
    Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 13339.
  • 36
    Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 260311.
  • 37
    Kannel WB. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther 1997; 11 Suppl 1: 199212.
  • 38
    Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 14752.
  • 39
    Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 34652.
  • 40
    Peto R. Two properties of multiple regression analysis and regression to the mean (and regression from the mean). In: FletcherCM, PetoR, TinkerCM, SpeizerFE eds The Natural History of Chronic Bronchitis and Emphysema. An eight year study of early Chronic Obstructive Lung Disease in Working Men in London. Oxford: Oxford University Press, 1976; 21823.